Thrombophilia and arterial disease. An up-to-date review of the literature for the vascular surgeon

International Angiology

Volumn 22, Issue 2, 2003, Pages 116-124

  Bohm G ^a   Al Khaffaf, H ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b BURNLEY GENERAL HOSPITAL   (United Kingdom)

Author keywords

Activated protein C resistance; Antiphospholipid syndrome; Arterial occlusive diseases; Factor V; Hyperhomocysteinaemia; Prothrombin, genetics; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PHOSPHOLIPID ANTIBODY; PLASMINOGEN; PROTEIN C; PROTEIN S; PROTHROMBIN; PYRIDOXINE; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN III DEFICIENCY; ARTERIOGRAPHY; ARTERY THROMBOSIS; CLINICAL PRACTICE; ECHOGRAPHY; EVIDENCE BASED MEDICINE; FAMILY STUDY; GENETIC COUNSELING; GENETIC DISORDER; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC SCREENING; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPOTHESIS; MEDLINE; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; SURGEON; THROMBOPHILIA; VASCULAR SURGERY; VEIN THROMBOSIS;

ARTERIAL OCCLUSIVE DISEASES; HUMANS; RISK ASSESSMENT; RISK FACTORS; THROMBOPHILIA; VASCULAR SURGICAL PROCEDURES; VENOUS THROMBOSIS;

EID: 16744367098     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Bauer KA, Goodnight SH, Ridker PM. Hypercoagulable states. Translation of risk factors to clinical practice. In: Hematology American Society of Hematology Education Program Book; 1998.p.255-73.
2. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004.
3. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
4. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW et al. Association of idiopathic venous thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994;343:1535-6.
5. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993;39: 1764-79.
6. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Saron SR, Secic M et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 1994;40:873-81.
7. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)-inemia as a risk factor for occlusive vascular disease. Ann Rev Nutr 1992;12:279-98.
8. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
9. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473-501.
10. McCully KS. Homocysteine and vascular disease. Nat Med 1996;2:386-9.
11. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood 1996;87:3531-44.
12. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
13. Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL et al. Myocardial infarction in youg women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997;96:412-7.
14. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
15. Genest JJ Jr, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990;16:1114-9.
16. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324: 1149-55.
17. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US Physicians. JAMA 1992;268:877-81.
18. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9.
19. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ et al. Association between plasma homocysteine concentrations and extracranial carotidartery stenosis. N Engl J Med 1995;332:286-91.
20. Selhub J, Jacques PF, Rosenberg IH, Rogers G, Bowman BA, Gunter EW et al. Serum total homocysteine concentrations in the third National Health and Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999:131:331-9.
21. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999;131:352-5.
22. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001;73:613-21.
23. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
24. den Heijer M, Koster T, Blom HU, Bos GM, Brier E, Reitsma PH et al. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med 1996;334: 759-62.
25. Bellamy MF, McDowell IFW. Putative mechanisms for vascular damage by homocysteine. J Inher Metab Dis 1996;20:307-15.
26. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997;277:1775-81.
27. Still RA, McDowell IFW. Clinical implications of plasma homocysteine measurement in cardiovascular disease. J Clin Pathol 1998;51:183-8.
28. Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE et al. Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009-15.
29. Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989;16:482-9.
30. Asherson RA. A "primary" antiphospholipid syndrome? J Rheumatol 1988;15:1742-6.
31. Harris EN, Asherson RA, Hughes GRV. Antiphospholipid antibodies - autoantibodies with a difference. Ann Rev Med 1988;39:261-71.
32. Goodnight SH. Antiphospholipid antibodies and thrombosis. Curr Opin Hematol 1994;1:354-61.
33. Roubey RA, Hoffman M. From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet 1997;350:1491-3.
34. Horbach DA, Van Oort E, Derksen RHWM, de Groot PG. The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity. Discrimination between functional and non-functional anti-prothrombin-antibodies. Thromb Haemost 1998;79:790-5.
35. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120-4.
36. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
37. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336:177-8.
38. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 1990;20:231-6.
39. Vila P, Hernandez MC, Lopez-Fernandez MF, Battle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994;72:209-13.
40. Olee T, Pierangeli SS, Handley HH, Le DT, Wei X, Lai CJ et al. A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Proc Natl Acad Sci U S A 1996;93:8606-11.
41. Cacoub P, Musset L, Amoura Z, Guilani P, Chabre H, Lunel F et al. Anicardiolipin, anti-β2-glycoprotein I, and antinucleosome antibodies in hepatitis C virus infection and mixed Cryoglobulinemia. J Rheumatol 1997;24:2139-44.
42. Price BE, Rauch J, Shia MA, Walsh MT, Lieberthal W, Gilligan HM et al.Antiphospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a β2-glycoprotein I-dependent manner. J Immunol 1996;157:2201-8.
43. Casciola-Rosen L, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci U S A 1996;93:1624-9.
44. Levine SR, Salowich-Palm L, Sawaya KL, Perry M, Spencer HJ, Winkler HJ et al. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997;28:1660-5.
45. Levine SR, Brey RL, Sawaya KL, Salowich-Palm L, Kokkinos J, Kostrzema B et al. Recurrent stroke and thrombo-occlusive events in the antiphopholipid syndrome. Ann Neurol 1995;38:119-24.
46. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993;43:2069-73.
47. Muir KW, Squire IB, Alwan W, Lees KR. Anticardiolipin antibodies in an unselected stroke population. Lancet 1994;344:452-6.
48. The Antiphospholipid Antibodies and Stroke Study Group (APASS). Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology 1997;48:91-4.
49. Vaarala O, Mänttäri M, Manninen V, Tenkanen L, Puurunen M, Aho K et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23-7.
50. Wu RH, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17:3159-63.
51. Zuckerman E, Toubi E, Shiran A, Sabo E, Shmuel Z, Golan TD et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus patients: a controlled prospective study. Am J Med 1996;101:381-6.
52. Taylor Jr LM, Chitwood RW, Dalman RL, Sexton G, Goodnight SH, Porter JM. Antiphospholipid antibodies in vascular surgery patients. A cross-sectiional study. Ann Surg 1994;220:544-51.
53. Lee RW, Taylor LM, Landry GJ, Goodnight SH, Moneta GL, Edwards JM et al. Prospective comparison of infrainguinal bypass grafting in patients with and without antiphospholipid antibodies. J Vasc Surg 1996;24:524-33.
54. Lam EY, Taylor LM, Landry GJ, Porter JM, Moneta GL. Relatioship between antiphospholipid antibodies and progression of lower extremity arterial occlusive disease after lower extremity bypass operations. J Vasc Surg 2001;33:976-82.
55. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
56. Koster T, Rosendaal FR, De Ronde F, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study. Lancet 1993;342:1503-6.
57. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost 1993;70:1067-91.
58. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330: 517-21.
59. Svensson PJ, Zöller B, Mattiasson I, Dahlbäck B. The factor V R506Q mutation causing APC-resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med 1997;241:379-85.
60. Ouriel K, Green RM, DeWeese JA, Cimino C. Activated protein C resistance: prevalence and implications in peripheral vascular disease. J Vasc Surg 1996;23:46-51.
61. Donaldson MC, Belkin M, Whittemore AD, Mannick JA, Longtine JA, Dorfman DM. Impact of activated protein C resistance on general vascular sugical patients. J Vasc Surg 1997;25:1054-60.
62. Sampram ESK, Lindblad B, Dahlbäck B. Activated protein C resistance in patients with peripheral vascular disease. J Vasc Surg 1998;28:624-9.
63. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998;97:1037-41.
64. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
65. Vargas M, Soto I, Pinto CR, Urgelles MF, Batalla A, Rodriguez-Reguero J et al. The prothrombin 20210A allele and the factor V Leiden are associated with venous thrombosis but not with early coronary artery disease. Blood Coag Fibrinol 1999;10:39-41.
66. Redondo M, Watzke HH, Stucki B, Sulzer F, Demarmels Biasiutti F, Binder BR et al. Coagulation factors II, V, VII, and X, Prothrombin Gene 20210G→A transition, and Factor V Leiden in coronary artery disease. High Factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19: 1020-5.
67. Holm J, Hillarp A, Zöller B, Erhardt L, Berntorp E, Dahlbäck B. Factor V Q 506 (resistance to activated protein C) and prognosis after acute coronary syndrome. Thromb Haemost 1999;81:857-60.
68. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variant in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
69. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siscovick DS et al. Geographic distribution of the 20210G to A prothrombin variant. Thromb Haemost 1998;79:706-8.
70. Arruda VR, Annichino-Bizzacchi JM, Gonçalves MS, Costa FF. Prevalence of the prothrombine gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997;78:1430-3.
71. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in the prothrombin gene and the risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999;99:999-1004.
72. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-50.
73. Arruda VR, Siquiera LH, Chiaparini LC, Coelho OR, Mansur AP, Ramires A et al. Prevalence of the prothrombin gene variant 20210G→A among patients with myocardial infarction. Cardiovasc Res 1998;37:42-5.
74. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol 1997;17:2418-22.
75. Croft SA, Daly ME, Steeds RP, Channer KS, Samani NJ, Hampton KK. The prothrombin 20210A allele and its association with myocardial infarction. Thromb Haemost 1999;81:861-4.
76. Heller RF, Chinn S, Tunstall Pedoe HD, Rose G. How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project. BMJ 1984;288:1409-11.
77. Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM et al. Apolipoproteins and ischaemic heart disease: Implications for screening. Lancet 1994;343:75-9.
78. Lowe GDO, Fowkes FGR, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh artery study. Circulation 1993;87:1915-20.
79. Heinrich J, Schulte H, Schönfeld R, Köhler E, Assmann G. Association of variables of coagulation, fibrinolysis, and acute phase with atherosclerosis in coronary and peripheral arteries supplying the brain. Thromb Haemost 1995;73:374-9.
80. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor I (PAI-1) promotor polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995;74:1032-4.
81. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo J, for the European Concerted Action on Thrombosis, and Disabilities Angina Pectoris Study group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
82. Bauer KA. The hypercoagulable state: evaluation and management. Update on thrombophilia. In: American Society of Hematology education session; 1999.p.231-5.
83. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, DiAngelo A et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaboration study (ISCOAT). Lancet 1996;348:423-8.
84. Rand JH, Luong T-H. Thrombophilias: diagnosis and treatment of thrombophilia relating to contraception and pregnancy. Semin Hematol 1999;36:2-9.
85. Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 2000;51:169-85.
86. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303-8.
87. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-7.
88. Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzucconi MG, Schinco PC et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four year prospective study from the Italian Registry. Am J Med 1996;100:530-6.
89. Greaves M, Cohen H, Macttin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704-15.